Effects of Short-term Fasting on Ghrelin/GH/IGF-1 Axis in Healthy Humans: The Role of Ghrelin in the Thrifty Phenotype.
energy expenditure
fasting
ghrelin
growth hormone
thrifty phenotype
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
18 08 2022
18 08 2022
Historique:
received:
14
02
2022
pubmed:
10
6
2022
medline:
23
8
2022
entrez:
9
6
2022
Statut:
ppublish
Résumé
A greater decrease in 24-hour energy expenditure (24hEE) during short-term fasting is indicative of a thrifty phenotype. As ghrelin and the growth hormone (GH)/insulin-like growth factor 1 (IGF-1) axis are implicated in the regulation of energy intake and metabolism, we investigated whether ghrelin, GH, and IGF-1 concentrations mediate the fasting-induced decrease in 24hEE that characterizes thriftiness. In 47 healthy individuals, 24hEE was measured in a whole-room indirect calorimeter both during 24-hour eucaloric and fasting conditions. Plasma total ghrelin, GH, and IGF-1 concentrations were measured by enzyme-linked immunosorbent assay after an overnight fast the morning before and after each 24-hour session. During 24-hour fasting, on average 24hEE decreased by 8.0% (P < .001), GH increased by ~5-fold (P < .001), whereas ghrelin (mean +23 pg/mL) and IGF-1 were unchanged (both P ≥ .19) despite a large interindividual variability in ghrelin change (SD 150 pg/mL). Greater fasting-induced increase in ghrelin was associated with a greater decrease in 24hEE during 24-hour fasting (r = -0.42, P = .003), such that individuals who increased ghrelin by 200 pg/mL showed an average decrease in 24hEE by 55 kcal/day. Short-term fasting induced selective changes in the ghrelin/GH/IGF-1 axis, specifically a ghrelin-independent GH hypersecretion that did not translate into increased IGF-1 concentrations. Greater increase in ghrelin after 24-hour fasting was associated with greater decrease in 24hEE, indicating ghrelin as a novel biomarker of increased energy efficiency of the thrifty phenotype.
Identifiants
pubmed: 35678263
pii: 6604640
doi: 10.1210/clinem/dgac353
pmc: PMC9387714
doi:
Substances chimiques
Ghrelin
0
IGF1 protein, human
0
Human Growth Hormone
12629-01-5
Insulin-Like Growth Factor I
67763-96-6
Growth Hormone
9002-72-6
Banques de données
ClinicalTrials.gov
['NCT00523627']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3769-e3780Informations de copyright
Published by Oxford University Press on behalf of the Endocrine Society 2022.
Références
Am J Clin Nutr. 1967 Nov;20(11):1212-22
pubmed: 6057588
Am J Clin Nutr. 2019 Sep 1;110(3):593-604
pubmed: 31172178
Growth Horm IGF Res. 1998 Apr;8 Suppl B:49-59
pubmed: 10990135
J Clin Diagn Res. 2014 Aug;8(8):MC13-7
pubmed: 25302229
J Clin Endocrinol Metab. 2004 Jan;89(1):335-43
pubmed: 14715869
Int J Obes (Lond). 2006 Feb;30(2):293-6
pubmed: 16247504
Eur J Endocrinol. 2005 Jun;152(6):845-50
pubmed: 15941923
J Clin Invest. 1988 Apr;81(4):968-75
pubmed: 3127426
J Clin Endocrinol Metab. 1996 Dec;81(12):4379-84
pubmed: 8954045
J Endocrinol Invest. 1999 Apr;22(4):313-5
pubmed: 10342368
Am J Physiol. 1999 Aug;277(2):E245-52
pubmed: 10444419
J Clin Endocrinol Metab. 1998 Feb;83(2):362-9
pubmed: 9467542
J Clin Endocrinol Metab. 2013 Jul;98(7):2791-9
pubmed: 23666976
Nature. 2001 Jan 11;409(6817):194-8
pubmed: 11196643
Neurosci Lett. 2003 Oct 2;349(2):75-8
pubmed: 12946556
Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E814-22
pubmed: 15972272
J Clin Endocrinol Metab. 2001 Dec;86(12):5992
pubmed: 11739476
J Clin Endocrinol Metab. 1994 Apr;78(4):960-7
pubmed: 7512573
Int J Obes. 1982;6(1):23-8
pubmed: 7068313
Metabolism. 2020 Sep;110:154303
pubmed: 32599082
J Clin Endocrinol Metab. 2018 Mar 1;103(3):1077-1087
pubmed: 29300902
Clin Endocrinol (Oxf). 1994 Jan;40(1):103-10
pubmed: 8306468
Endocrinology. 2002 Jan;143(1):185-90
pubmed: 11751608
Clin Endocrinol (Oxf). 2002 Oct;57(4):539-46
pubmed: 12354137
Horm Res. 1993;40(1-3):37-47
pubmed: 8300049
J Clin Endocrinol Metab. 2004 Dec;89(12):5993-7
pubmed: 15579749
J Clin Invest. 1986 Dec;78(6):1568-78
pubmed: 3782471
Am J Clin Nutr. 2007 Sep;86(3):625-32
pubmed: 17823426
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
Arch Dis Child. 1991 May;66(5):598-602
pubmed: 2039249
Obesity (Silver Spring). 2019 May;27(5):691-699
pubmed: 31012296
Diabetes. 2013 Dec;62(12):4043-51
pubmed: 23974925
J Clin Endocrinol Metab. 2004 Feb;89(2):936-9
pubmed: 14764817
Mol Pharm. 2012 Feb 6;9(2):281-9
pubmed: 22149064
Curr Drug Targets. 2005 Mar;6(2):153-69
pubmed: 15777186
Diabetes. 2001 Aug;50(8):1714-9
pubmed: 11473029
J Clin Endocrinol Metab. 2000 Dec;85(12):4908-11
pubmed: 11134161
J Clin Endocrinol Metab. 2020 May 1;105(5):
pubmed: 32118268
J Clin Endocrinol Metab. 2005 Feb;90(2):741-6
pubmed: 15522942
Endocr Rev. 2009 Apr;30(2):152-77
pubmed: 19240267
Miner Electrolyte Metab. 1998;24(4):273-8
pubmed: 9554567
Sci Rep. 2022 Feb 17;12(1):2679
pubmed: 35177705
Int J Obes (Lond). 2016 May;40(5):754-60
pubmed: 26499440
Eur J Endocrinol. 2002 Feb;146(2):203-7
pubmed: 11834429
Am J Physiol. 1988 Sep;255(3 Pt 1):E332-7
pubmed: 3421330
J Clin Endocrinol Metab. 2003 Jul;88(7):3292-8
pubmed: 12843178
Nutr Metab (Lond). 2016 Jul 22;13:47
pubmed: 27453716
J Clin Epidemiol. 2001 Apr;54(4):343-9
pubmed: 11297884
Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):619-24
pubmed: 24100676
Endocrinology. 2002 Mar;143(3):792-800
pubmed: 11861499
Nature. 2000 Oct 19;407(6806):908-13
pubmed: 11057670
Diabetes. 2015 Aug;64(8):2859-67
pubmed: 25964395
Front Endocrinol (Lausanne). 2018 Apr 09;9:117
pubmed: 29686648
Curr Obes Rep. 2020 Jun;9(2):121-135
pubmed: 32248352
Int J Obes Relat Metab Disord. 1998 Sep;22(9):836-41
pubmed: 9756240